TORONTO - Apotex Health Corp.'s CEO says the generic drug maker expects to have more opportunities for growth as a public company, even though being publicly traded can come with
TORONTO - Apotex Health Corp.‘s CEO says the generic drug maker expects to have more opportunities for growth as a public company, even though being publicly traded can come with more pressure.
Jeff Watson says capital raised from the initial public offering can also be used to reduce debt and provide more flexibility on Apotex’s balance sheet.
TORONTO - Apotex Health Corp. says it has filed a preliminary prospectus for an initial public offering that will see the…
Apotex Health Corp. filed for a Toronto Stock Exchange IPO that could raise up to C$1.2 billion, backed by C$3.5B in revenue and…
Canadian generic drugmaker Apotex Health Corp. filed for an initial public offering in Toronto. Find out more.
Canadian generic drugmaker Apotex Health Corp.'s dominance could be leveraged into future higher-margin categories. Find out more
TORONTO - Drug company Apotex Health Corp. says it is looking to sell about $1 billion worth of shares in its initial public…
Drug company Apotex Health Corp. is increasing the size of its initial public offering to about $1.3 billion, up from its earlier…
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
eXoZymes Inc. Announces Closing of $6 Million Public Offering
Can You Invest in Anthropic Before Its IPO?
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program - Ocular Therapeutix (NASDAQ:OCUL)
